Skip to main content
ArticleOPEN ACCESS

Correction to: ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity (Molecular Cancer, (2021), 20, 1, (12), 10.1186/s12943-020-01306-2)

Molecular Cancer
DOI: 10.1186/s12943-021-01319-5
0Citations
Citations of this article
4Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Following the publication of the original paper [1], the authors found out that the supplementary material is incomplete. Thus, the publication of correction to notify the readers on the error. Updated supplementary file is provided in this article.

Cite

CITATION STYLE

APA

Cheli, Y., Tulic, M. K., El Hachem, N., Nottet, N., Jacquel, A., Gesson, M., … Ballotti, R. (2021, December 1). Correction to: ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity (Molecular Cancer, (2021), 20, 1, (12), 10.1186/s12943-020-01306-2). Molecular Cancer. BioMed Central Ltd. https://doi.org/10.1186/s12943-021-01319-5

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free